Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a “Pituitary Society” survey

Lisa B. Nachtigall, Niki Karavitaki, Katja Kiseljak-Vassiliades, Luma Ghalib, Hidenori Fukuoka, Luis V. Syro, Daniel Kelly, Maria Fleseriu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. Methods: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. Results: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAs in patients with normal function. Conclusions: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice.

Original languageEnglish (US)
JournalPituitary
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Gadolinium
Pituitary Neoplasms
Contrast Media
Magnetic Resonance Imaging
Physicians
Brain
Adenoma
Radiotherapy
Surveys and Questionnaires
Neurosurgeons
Kidney
Safety
Education
Endocrinologists

Keywords

  • Adenoma
  • Contrast
  • Gadolinium
  • Imaging
  • Neuroendocrinologists
  • Neurosurgeons
  • Pituitary
  • Safety
  • Survey
  • Tumor

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors : a “Pituitary Society” survey. / Nachtigall, Lisa B.; Karavitaki, Niki; Kiseljak-Vassiliades, Katja; Ghalib, Luma; Fukuoka, Hidenori; Syro, Luis V.; Kelly, Daniel; Fleseriu, Maria.

In: Pituitary, 01.01.2018.

Research output: Contribution to journalArticle

Nachtigall, Lisa B. ; Karavitaki, Niki ; Kiseljak-Vassiliades, Katja ; Ghalib, Luma ; Fukuoka, Hidenori ; Syro, Luis V. ; Kelly, Daniel ; Fleseriu, Maria. / Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors : a “Pituitary Society” survey. In: Pituitary. 2018.
@article{dd0bd3d301d245c49943dfcd34bec21c,
title = "Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a “Pituitary Society” survey",
abstract = "Purpose: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. Methods: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. Results: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAs in patients with normal function. Conclusions: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice.",
keywords = "Adenoma, Contrast, Gadolinium, Imaging, Neuroendocrinologists, Neurosurgeons, Pituitary, Safety, Survey, Tumor",
author = "Nachtigall, {Lisa B.} and Niki Karavitaki and Katja Kiseljak-Vassiliades and Luma Ghalib and Hidenori Fukuoka and Syro, {Luis V.} and Daniel Kelly and Maria Fleseriu",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s11102-018-0924-0",
language = "English (US)",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors

T2 - a “Pituitary Society” survey

AU - Nachtigall, Lisa B.

AU - Karavitaki, Niki

AU - Kiseljak-Vassiliades, Katja

AU - Ghalib, Luma

AU - Fukuoka, Hidenori

AU - Syro, Luis V.

AU - Kelly, Daniel

AU - Fleseriu, Maria

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. Methods: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. Results: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAs in patients with normal function. Conclusions: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice.

AB - Purpose: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. Methods: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. Results: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAs in patients with normal function. Conclusions: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice.

KW - Adenoma

KW - Contrast

KW - Gadolinium

KW - Imaging

KW - Neuroendocrinologists

KW - Neurosurgeons

KW - Pituitary

KW - Safety

KW - Survey

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=85056820811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056820811&partnerID=8YFLogxK

U2 - 10.1007/s11102-018-0924-0

DO - 10.1007/s11102-018-0924-0

M3 - Article

C2 - 30456434

AN - SCOPUS:85056820811

JO - Pituitary

JF - Pituitary

SN - 1386-341X

ER -